The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels to provide expanded guidance to health care professionals on how to safely decrease or discontinue these medications in patients who are physically dependent on them. The agency said it has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased, a safety concern it continues to track.

Related News Articles

Headline
The Drug Enforcement Administration this week proposed reducing aggregate production quotas for five opioid controlled substances in 2020.
Headline
The Department of Health and Human Services today announced more than $1.8 billion in funding to states to combat the opioid crisis by expanding access to…
Headline
The AHA today responded to an HHS request for input from health care providers and other stakeholders on ensuring legitimate access to controlled substances…
Headline
The Health Resources and Services Administration yesterday awarded 80 rural consortia $1 million each to help prevent, treat and support recovery for patients…
Headline
The National Association of Attorneys General yesterday urged congressional leaders to remove federal barriers to opioid use disorder treatment.
Headline
The number of naloxone prescriptions dispensed from retail pharmacies doubled in 2018, but access to the emergency opioid overdose treatment still varies…